Analgesics, Non-Narcotic
12
2
2
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
16.7%
2 terminated out of 12 trials
66.7%
-19.8% vs benchmark
42%
5 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
Telehealth Delivered Physical Rehabilitation for an Ankle Sprain
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Dexmedetomine as Adjuvant for Spinal Anesthesia in Elective Cesarian Sections : a Pilot Study
Opioid-free Anesthesia in Thyroidectomies
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Lidocaine and Magnesium and Ketamine in Gynecological Surgery
Opioid-free Anesthesia With a Mixture of Dexmedetomidine-lidocaine-ketamine
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy